Xenetic reports Q2 EPS (83c) vs. (69c) last year

Reports Q2 revenue $726,404 vs. $651,005 last year. “We remain confident in the potential of our DNase-based oncology platform and continue to advance our preclinical studies with data expected before year end. Looking ahead, we are focusing our resources on driving our pipeline towards first-in-human clinical studies and establishing proof-of-concept in multiple indications. Our goal remains unwavering and we are committed to bringing a much-needed, innovative immune-oncology treatment to patients and generating shareholder value in the near and long term,” commented, James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.